SCHEMBL31388752

SCHEMBL31388752

CC(C)(C)OC(=O)NC1(c2cnc(Br)cn2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.35
FPR3 P25089 2/20 0.34
FPR2 P25090 2/20 0.34
KIT P10721 2/20 0.33
AKT2 P31751 1/20 0.33
TRPA1 O75762 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
TSHR P16473 1/20 0.32
FSHR P23945 1/20 0.32
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2392301 0.86 AKT1 (0.38) AKT1FPR3FPR2KITTRPA1
SCHEMBL5519762 0.84 DGAT1 (0.41) AKT1FPR3FPR2KITTRPA1
SCHEMBL2713905 0.81 AKT1 (0.42) AKT1FPR3FPR2KITAKT2
SCHEMBL20907535 0.79 DGAT1 (0.40) AKT1FPR3FPR2KITAKT2
SCHEMBL31388863 0.79 GAA (0.32) FPR3FPR2NPC1RAB9ARECQL
SCHEMBL2712721 0.79 AAK1 (0.37) AKT1FPR3FPR2KITTRPA1
SCHEMBL30912431 0.78 AKT1 (0.38) AKT1FPR2KITAKT2NPC1
SCHEMBL32683637 0.78 OPRM1 (0.43) AKT1KITTRPA1
SCHEMBL2391676 0.78 AKT1 (0.36) AKT1KITTRPA1RAB9AGSK3B
SCHEMBL2391034 0.77 AKT1 (0.36) AKT1KITTRPA1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410179-B2 Modulators of TNF alpha activity and uses thereof RAYTHERA, INC. (US) 2025-09-09 US disclosed
US-20250263418-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. 2025-08-21 US disclosed
US-20250066375-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. 2025-02-27 US disclosed
WO-2025038927-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF RAYTHERA, INC. (US) 2025-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066375-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF TNF, TNFRSF1A, TNFRSF9 AKT1 1610/4885FPR3 988/4885FPR2 755/4885
US-12410179-B2 Modulators of TNF alpha activity and uses thereof TNF, TNFRSF1A, TNFRSF9 AKT1 1610/4885FPR3 988/4885FPR2 755/4885
US-20250263418-A1 MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF TNF, TNFRSF1A, TNFRSF9 AKT1 1610/4885FPR3 988/4885FPR2 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.